Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.47 |
| ▸ | GRM6 | O15303 | 6/20 | 0.47 |
| ▸ | GRM5 | P41594 | 6/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GRM8 | O00222 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158525 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL14158524 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL2229860 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL25660676 | 0.80 | SLC6A4 (0.65) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL5479431 | 0.80 | SLC6A4 (0.65) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL4755338 | 0.74 | SLC6A4 (0.59) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL9088184 | 0.71 | SLC6A4 (0.55) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL15514216 | 0.71 | SLC6A4 (0.55) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL1064244 | 0.70 | CYP1A2 (1.00) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E | |
| SCHEMBL1063416 | 0.70 | CYP1A2 (1.00) | SLC6A4CYP1A2ALOX15ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908850-B1 | Target for therapy of cognitive impairment | UNIV JOHNS HOPKINS (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2314289-A1 | Gaba receptor mediated modulation of neurogenesis | Braincells, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1567674-A4 | TARGET FOR THERAPY OF COGNITIVE IMPAIRMENT | UNIV JOHNS HOPKINS (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7129073-B2 | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways | THE ROCKEFELLER UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060223158-A1 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-05 | — | — | US | disclosed |
| EP-1567674-A2 | TARGET FOR THERAPY OF COGNITIVE IMPAIRMENT | The Johns Hopkins University (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040191803-A1 | Target for therapy of cognitive impairment | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-09-30 | — | — | US | disclosed |
| WO-2004048551-A2 | TARGET FOR THERAPY OF COGNITIVE IMPAIRMENT | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A4 1564/4885CYP1A2 4444/4885ALOX15 3185/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | SLC6A4 373/4885CYP1A2 4816/4885ALOX15 3050/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | SLC6A4 3551/4885CYP1A2 4835/4885ALOX15 3653/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | SLC6A4 1527/4885CYP1A2 4681/4885ALOX15 2823/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | SLC6A4 716/4885CYP1A2 4621/4885ALOX15 1929/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | SLC6A4 792/4885CYP1A2 4049/4885ALOX15 1046/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A4 1564/4885CYP1A2 4444/4885ALOX15 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.